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Human papillomavirus (HPV) 58 is a high-risk HPV type associated with progression to invasive
genital carcinomas. We developed six monoclonal antibodies (mAbs) against HPV58 L1 virus-like
particles that bind conformational epitopes on HPV58. The hybridoma cell lines were adapted to
serum- and animal component-free conditions and the mAb supernatants were affinity-purified.
The six mAbs neutralized HPV58 pseudoviruses (PsVs) and ‘quasivirions’ with different
capacities. The mAbs differed in their ability to prevent PsV58 attachment to HaCaT cells, to the
extracellular matrix (ECM) deposited by HaCaT cells, to heparin and to purified human laminin 5,
a protein in the ECM. These mAbs provide a unique set of tools to study the binding properties of
a previously untested, high-risk HPV type and the opportunity to compare these characteristics
with the binding of other HPV types.
Human papillomaviruses (HPVs) are small, non-enveloped
viruses with an 8 kb double-stranded DNA genome
encapsidated in a structure consisting of 72 capsomers
composed of pentameric L1 protein. There is also a minor
capsid protein, L2, that has not been characterized fully
(Kirnbauer et al., 1993). The recent vaccines Gardasil and
Cervarix, approved for use in humans, include L1 virus-
like particle (VLP) antigens of the high-risk HPV types for
cervical cancer, HPV16 and 18, and Gardasil also includes
the low-risk HPV types 6 and 11 (Harper et al., 2006;
Schmiedeskamp & Kockler, 2006; Stanley, 2006; Villa et al.,
2005). HPV types 31, 33, 39, 45, 52 and 58 are the next
most frequently detected genotypes in cervical cancers after
HPV16 and 18 (Munoz et al., 2003). HPV58 is considered
worldwide to be a rare type, but is prevalent in cervical
cancers in eastern Asia (Chan et al., 2002). In Mexico,
HPV58 was found in all grades of lesions at a frequency
equal to or higher than HPV16 (Gonzalez-Losa et al.,
2004). Several researchers have indicated that HPV58 needs
to be included in a second-generation HPV vaccine in
order to provide better protection in Asia and Africa
(Bhatla et al., 2008; Fukuchi et al., 2009; Xi et al., 2003). To
date, there are no published monoclonal antibody (mAb)
reagents to HPV58, making study of the binding and
neutralization properties of this virus type difficult.
Previously, we demonstrated that HPV11 virion infection is
blocked by varying degrees of epitope saturation by HPV11-
specific mAbs (Christensen et al., 1994). Neutralization of
HPV11 virions is also achieved by several monovalent Fab
fragments and single-chain variable fragments (scFv) (Culp
et al., 2007). It was reported that mAbs to HPV16 (H16.V5,
H16.E70 and H16.U4) differ in the mechanisms utilized to
neutralize HPV16 pseudoviruses (PsVs) (Day et al., 2007).
V5 and E70 did not prevent attachment of the capsids to the
cell surface, but did block their binding to the extracellular
matrix (ECM). U4 blocked binding to the cell surface, but
not to the ECM.
Most reports describe studies that are conducted with
HPV11, 16 or 31 and there are few data comparing the
binding patterns of capsids and virions of different HPV
types to human keratinocytes and to the ECM secreted by
these cells (Culp et al., 2006b; Day et al., 2003; Selinka et al.,
2007; Smith et al., 2007). A recent publication compares
HPV16, 31 and 5 PsVs binding to the murine genital
tract (Johnson et al., 2009). Data from our laboratory
demonstrate that there are differences in binding properties
between VLPs of HPV11, 16, 18 and 45 to HaCaT cells and
ECM, demonstrating that it is important to study several
different HPV types to determine binding and uptake
differences and similarities in vitro and ultimately in vivo
(Broutian et al., 2010). Type-specific reagents, including
mAbs, are needed to study properties of individual HPV
types, as cross-reactivity is limited among mAbs (Rizk et al.,
2008).
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neutralizing HPV58 mAbs and determined their binding
and neutralization titres. We then tested the ability of the
mAbs to inhibit the binding of PsV58 to heparin–BSA and
purified human laminin 5 (LN5) and to HaCaT cells and
ECM. These mAbs will be useful tools in determining the
neutralizing epitopes on HPV58 capsids and comparing the
binding and entry mechanisms of HPV58 with those of
other HPV types.
HPV58 L1 VLPs and pseudovirions (L1 and L2 encapsidat-
ing a pYSEAP genome) were prepared as described
previously (Buck et al., 2005; Pastrana et al., 2004).
‘Quasivirions’ (QVs), a term coined by our laboratory to
describe virions with an authentic papillomavirus genome
produced in 293TT cells, were prepared as described
previously (Mejia et al., 2006; Pyeon et al., 2005). For this
study, HPV58 L1 and L2 encapsidate an HPV11 genome.
Hybridomas secreting HPV58 L1-specific mAbs were
generated as described previously using Ribi adjuvant
(Corixa) (Christensen et al., 1990, 1996). Hybridoma cell
lines were adapted to serum-free conditions in animal
component-free media (BD Biosciences) and supernatants
were purified on Protein A affinity columns for all IgG
mAbs. The single IgM mAb was purified on an immobilized
mannan-binding protein column (Pierce). mAb protein
concentrations were determined by A280 readings. PsV, VLP
and QV protein concentrations were determined by BCA
protein assay (Pierce). Approximately 9.75610
9 VLPs or
PsV particles were used in ELISA binding assays to
determine the mAbs’ reactivity against HPV58 PsVs and
L1 VLPs [Christensen et al., 1996; Schiller laboratory
technical file 129 (http://ccr.cancer.gov/staff/links.asp?
profileid=5637)].
Neutralization assays with PsV58 were performed in 293TT
cells as described previously (Buck et al., 2005; Pastrana
et al., 2004). Approximately 1.6610
5 PsVs per cell were
incubated with indicated dilutions of mAbs for 1 h at
37 uC before adding to duplicate wells. Two days post-
seeding, 30 ml cell-culture supernatant was assayed with
pNPP (Sigma). Neutralization of QVs was performed in
HaCaT cells and 293TT cells, where approximately
1.38610
6 QVs per cell were incubated with dilutions of
mAbs before adding to cells. Seventy-two hours post-
seeding, cells were harvested with TRIzol (Invitrogen) and
total RNA was extracted. E1^E4 transcripts were deter-
mined with quantitative (Q) RT-PCR and REST analysis as
described previously (Culp & Christensen, 2003).
ELISA binding assays to heparin–BSA and LN5 were
conducted as described previously (Culp et al., 2006b) with
minor modifications. Heparin–BSA- or mAb affinity
column-purified human LN5 (200 ng per well) was coated
onto microtitre plates (Evergreen Scientific) overnight at
4 uC. PsVs were incubated overnight at 4 uC with 100 ng
mAbs ml
21 in PBS. Pre-incubated PsVs or PsVs alone were
added to milk protein-blocked duplicate wells for 1 h at
room temperature. After washing, a rabbit polyclonal
antibody raised against HPV58 L1 VLPs was added in 5%
milk PBS/T followed by an anti-rabbit secondary antibody
(Pierce) conjugated to alkaline phosphatase.
Immunofluorescence studies of mAb inhibition of PsV58
binding to HaCaT cells and ECM were described previously
(Culp et al., 2006a).PsV58 (10 mgm l
21) wasincubated with
100 ng mAbs ml
21 overnight at 4 uC, added to fixed HaCaT
cells and ECM and detected by a pool of the H58 mAbs.
Fluorophore-labelled secondary antibodies were goat anti-
mouse–Alexa Fluor 488 IgG and donkey anti-rabbit–Alexa
Fluor 594 (Invitrogen). All coverslips were stained with
Hoechst 33342 (Molecular Probes) to detect cellular DNA.
Fluorescence microscopy was performed using a Nikon
Eclipse E600. Photographs were digitally prepared using
Adobe Photoshop. Within each figure, all images were
photographed and digitally prepared in an identical manner.
Six reactive hybridoma clones were selected for further
study: H58C8.8 (C8), H58D10.6 (D10), H58E5.1 (E5),
H58F3.1 (F3), H58G5.1 (G5) and H58J6.3 (J6). Binding
titres were determined by ELISA using intact or denatured
HPV58 L1 VLPs or intact HPV58 PsVs. All six mAbs
detected a conformationally sensitive epitope of HPV58 L1
VLPs or PsVs, as none bound to denatured L1 VLPs (data
not shown). The binding profiles of the mAbs to HPV58
PsVs are shown in Fig. 1(a). The strongest half-maximal
binding titre for PsV58 was shown with mAb D10
(15 ng ml
21), whilst the lowest half-maximal titre was
with mAb G5 (700 ng ml
21). The half-maximal binding
titres to PsVs and L1 VLPs are shown in Table 1. The first
mAb to reach maximum absorbance was G5 (absorbance
1.62). Interestingly, the absorbance for mAb J6 was only
0.29 at the same time point, despite having an apparent
half-maximal binding titre of 100 ng ml
21 (same time
point data not shown). We wondered whether this
indicated that J6 has fewer epitope-binding sites than the
other mAbs. A capture ELISA was performed whereby
unconjugated goat anti-mouse antibody was bound to
ELISA wells in sodium carbonate pH 9.6 binding buffer,
followed by dilutions of the mAbs and secondary antibody.
mAb J6 showed the same detection pattern as in the PsV-
binding ELISA, indicating that the secondary antibody may
not detect IgG3 isotypes efficiently and that we therefore
cannot make conclusions about the number of epitope-
binding sites from the indirect ELISA. The half-maximal
binding titre for J6 is only an approximation, due to the
inefficiency of detection by the secondary antibody.
The neutralizing activities of the mAbs to PsV58 in 293TT
cells are shown in Fig. 1(b). The half-maximal neutralizing
titres determined for each mAb are shown in Table 1. mAb
J6 was the strongest neutralizer (0.2 ng ml
21). The
strongest binder, mAb D10, was the second-strongest
neutralizer at 0.4 ng ml
21. Not surprisingly, mAb G5 was
the weakest neutralizer (690 ng ml
21). These data indicate
that the approximate half-maximal binding titre for J6 may
not be accurate, as the half-maximal neutralization titre is
500-fold lower than the binding titre for PsVs.
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HPV11 genome to determine neutralization capacities in
human keratinocyte (HaCaT) cells and in 293TT cells.
293TT cells do not secrete LN5 into their ECM (Culp et al.,
2006a), so HaCaT cells were utilized as a more suitable
host-cell line. Table 1 shows the half-maximal binding
titres of three selected mAbs (D10, E5 and J6) as
determined by QRT-PCR and REST analysis of E1^E4
transcripts in HaCaT cells and 293TT cells (Culp &
Christensen, 2003; Mejia et al., 2006). Interestingly, the
Fig. 1. (a) Binding titres of mAbs to HPV58
PsVs, (b) neutralization of PsV58 and (c) mAb
inhibition of binding of PsVs to heparin–BSA
or LN5 by ELISA-based binding or neutraliza-
tion assays. One asterisk indicates a P-value of
,0.001 and two asterisks indicate a P-value of
,0.01. The absorbance is indicated on the
y-axis and the dilution of antibody (a, b) or well
treatment (c) is indicated on the x-axis. Each
figure is representative of three separate
experiments.
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three mAbs tested, although those for D10 and J6 were only
2-fold higher. The neutralization titre for mAb E5 was 7.5-
fold higher. Also, the neutralization titres for QVs in both
cell lines were much higher than that for PsVs in 293TT
cells. This is probably a direct result of the higher capsid
doses utilized for QVs in order to achieve sufficient E1^E4
transcripts and the different quantitative end points
(E1^E4 transcripts versus secreted alkaline phosphatase
and colorimetric readings). These data also indicate that
HPV58 may infect by unique pathways, depending on the
receptors available in the cells and/or ECM, but further
studies need to be completed comparing different host-cell
lines.
Next, we were interested in determining whether the mAbs
could inhibit PsV58 binding to heparin–BSA- and/or
purified human LN5-coated microtitre plates, as some
studies have suggested that heparan sulfates play a role in
virus–cell binding and infection (Combita et al., 2001; Day
et al., 2007; Joyce et al., 1999; Patterson et al., 2005; Selinka
et al., 2007). In addition, our laboratory has shown that
LN5 is important in HPV11 infection (Culp et al., 2006b).
H11.B2, a previously described mAb, was included as a
negative control (Christensen et al., 1990). The PsVs were
incubated with 100 ng mAbs ml
21 and detected by a rabbit
polyclonal antibody (pAb) raised against HPV58 L1 VLPs
(Rb58 pAb). We determined previously that Rb58 pAb can
detect PsV58–mAb complexes bound to uncoated ELISA
wells (data not shown). Fig. 1(c) shows that mAb G5 did
not block binding to either heparin–BSA or LN5. C8, D10,
F3 and J6 mAbs blocked binding to heparin–BSA and LN5
with P-values of ,0.001, as determined by Student’s t-test.
mAb E5 blocked binding to heparin–BSA with a P-value of
,0.001 and to LN5 with a P-value of ,0.01.
Binding characteristics of PsV58 to HaCaT cells and ECM
wereexaminedbyusingthepanelofmAbsasspecifictoolsfor
capsid detection. First, we performed immunofluorescence
assays, where it was determined that PsV58 binds to HaCaT
cells and also to the ECM secreted by these cells. A pool of the
mAbs at a total dilution of 1:1000 resulted in effective
detection of PsV58 on cells and ECM (data not shown).
Table 1. Binding and neutralization characteristics of H58 mAbs and neutralization titres of QV58 in 293TT and HaCaT cells
mAb Isotype Epitope Binding titre (ng ml
”1) PsV58 neutralization titre (ng ml
”1) QV neutralization (ng ml
”1) in:
PsVs VLPs HaCaT cells 293TT cells
H58C8 IgG1 C 18 29 1.2 – –
H58D10 IgG2a C 15 15 0.4 48 125
H58E5 IgG2a C 28 25 20 500 3800
H58F3 IgM C 200 175 6 – –
H58G5 IgG2b C 700 2250 690 – –
H58J6 IgG3 C ~100* ~1100* 0.2 400 600
*Half-maximal binding titres for J6 are approximate due to inefficient secondary antibody detection.
11.B2
C8
D10
E5
F3
G5
J6
(a) (b) (c)
Fig. 2. mAb inhibition of PsV58 binding to HaCaT cells or HaCaT-
derived ECM. (a) PsV58 binding to cells; (b) PsV58 binding to
ECM; (c) merge of PsV58 and LN5 staining. This figure is
representative of three separate experiments. Bars, 10mm.
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properties of VLPs and virions. PsV58 incubated with
100 ng mAbs ml
21 was added to fixed HaCaT cell cultures
or to HaCaT-derived ECM to test for binding inhibition.
PsV58 incubated with H11.B2 was included for each
experiment as a binding control (Fig. 2). A pAb to LN5 was
included on ECM staining. These experiments showed
several possible mechanisms for neutralization of PsV58 by
the panel of mAbs. mAbs C8 and D10 blocked binding of
PsV58 to HaCaT cells and ECM, as PsV58 binding was no
longer visible under our detection conditions. The other
four mAbs did not block binding of PsV58 to cells or to
ECM at this dilution. Taken into consideration with the
QV neutralization data in HaCaT cells, these findings
indicate that mAbs C8 and D10 probably neutralize by
inhibiting the PsV/QV from binding to host receptors on
the HaCaT cells and ECM. The other mAbs appear to
neutralize by a different mechanism, possibly by inhibiting
internalization of the PsVs/QVs or by blocking binding to a
potential secondary receptor.
All of the mAbs except G5 were able to block PsV58
binding to purified heparin–BSA and LN5 in an ELISA, but
only mAbs C8 and D10 were able to block fully the binding
to HaCaT cells and ECM at the same mAb concentration.
The ELISA tested the mAbs’ effectiveness at inhibiting
the PsV from binding to only one purified receptor/
component. HaCaT cells and ECM have multiple receptors
available for PsV binding, including heparan sulfates,
LN5 and a6 integrin among others. Collectively, these
observations confirm the complexity of the binding/
neutralization processes and indicate the possibility that
HPV capsids use several receptors on the cells and ECM for
infection. Purified mAbs are excellent reagents to deter-
mine binding and neutralization titres, as all cell-culture
contaminants have been removed. These mAbs will be
useful tools in determining the cell surface/ECM-binding
receptors of HPV58, for mapping the neutralizing epitopes
and for determining the internalization pathway of another
high-risk HPV type.
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